LATEST REVIEWS
Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Pai-Feng Hsu,
Shih-Hsien Sung,
Hao-Min Cheng,
Shyi-Jang Shin,
Kun-Der Lin,
Keong Chong,
Fu-Shun Yen,
Ben-Hui Yu,
Chi-Ting Huang,
Chih-Cheng Hsu,
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Antonios Douros,
Sophie Dell'Aniello,
Oriana Hoi Yun Yu,
Kristian B Filion,
Laurent Azoulay,
Samy Suissa,
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Hsien-Yen Chang,
Sonal Singh,
Omar Mansour,
Sheriza Baksh,
G Caleb Alexander,
Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
Shihchen Kuo,
Chun-Ting Yang,
Jin-Shang Wu,
Huang-Tz Ou,
Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK.
Krishnan Bhaskaran,
Isabel Dos-Santos-Silva,
David A Leon,
Ian J Douglas,
Liam Smeeth,
GO TO REVIEWS
